A retrospective cohort study of patients with T2DM and CVD or CV risk factors (e.g., hyperlipidemia, hypertension, obesity, smoking, or micro/macroalbuminuria) found high rates of prescribing SGLT2i (OR 3.94; 95% CI 3.90–3.99) or GLP-1 RA (OR 1.19; 95% CI 1.17–1.20) in patients at risk of CV (20). Here, GLP1R is linked to obesity disorder.